Autolus Therapeutics annual stock-based compensation
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Autolus Therapeutics Stock-Based Compensation Growth & History (AUTL)
Autolus Therapeutics's stock-based compensation was $14.4M for fiscal 2025.
View full Autolus Therapeutics company overviewAutolus Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $14.4M | −$1.0M | −6.68% |
| 2024 | 2024-12-31 | $15.5M | $4.3M | +38.09% |
| 2023 | 2023-12-31 | $11.2M | −$810,000 | −6.74% |
| 2022 | 2022-12-31 | $12.0M | $2.1M | +20.90% |
| 2021 | 2021-12-31 | $9.9M | −$10.1M | −50.37% |
| 2020 | 2020-12-31 | $20.0M | −$10.4M | −34.11% |
| 2019 | 2019-12-31 | $30.4M | — | — |
| 2018 | 2018-09-30 | $6.8M | $3.6M | +114.56% |
| 2017 | 2017-09-30 | $3.2M | $896,000 | +39.70% |
| 2016 | 2016-09-30 | $2.3M | — | — |
Autolus Therapeutics quarterly stock-based compensation
Q2.18
Q4.18
Q1.19
Q2.19
Q3.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.6M | $302,000 | +7.03% |
| Q1 2026 | 2026-03-31 | $3.6M | $698,000 | +24.35% |
| Q4 2025 | 2025-12-31 | $3.4M | −$2.8M | −44.76% |
| Q3 2025 | 2025-09-30 | $3.8M | −$185,000 | −4.60% |
| Q2 2025 | 2025-06-30 | $4.3M | $1.4M | +46.27% |
| Q1 2025 | 2025-03-31 | $2.9M | $583,000 | +25.53% |
| Q4 2024 | 2024-12-31 | $6.2M | $3.0M | +91.43% |
| Q3 2024 | 2024-09-30 | $4.0M | $1.2M | +40.36% |
| Q2 2024 | 2024-06-30 | $2.9M | $267,000 | +10.01% |
| Q1 2024 | 2024-03-31 | $2.3M | −$132,000 | −5.46% |
| Q4 2023 | 2023-12-31 | $3.3M | — | — |
| Q3 2023 | 2023-09-30 | $2.9M | −$473,000 | −14.17% |
| Q2 2023 | 2023-06-30 | $2.7M | — | — |
| Q1 2023 | 2023-03-31 | $2.4M | — | — |
| Q3 2022 | 2022-09-30 | $3.3M | — | — |
| Q1 2021 | 2021-03-31 | −$670,000 | −$6.9M | — |
| Q4 2020 | 2020-12-31 | $4.2M | −$2.3M | −35.58% |
| Q3 2020 | 2020-09-30 | $4.2M | −$3.3M | −43.99% |
| Q2 2020 | 2020-06-30 | $5.3M | −$3.6M | −40.16% |
| Q1 2020 | 2020-03-31 | $6.2M | −$1.1M | −15.34% |
| Q4 2019 | 2019-12-31 | $6.6M | $3.2M | +93.81% |
| Q3 2019 · Sep 30 | 2019-09-30 | $7.6M | $5.4M | +245.76% |
| Q3 2019 · Jun 30 | 2019-06-30 | $8.9M | $6.5M | +273.15% |
| Q2 2019 | 2019-03-31 | $7.4M | — | — |
| Q1 2019 | 2018-12-31 | $3.4M | — | — |
| Q4 2018 | 2018-09-30 | $2.2M | — | — |
| Q2 2018 | 2018-06-30 | $2.4M | — | — |
Autolus Therapeutics stock-based compensation trends
Over the last five fiscal years, Autolus Therapeutics's stock-based compensation decreased from $20.0M to $14.4M, a change of −$5.6M. The latest reported quarter, Q2 2026, shows $4.6M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Autolus Therapeutics source filings ↗